The media is reporting that Sanofi could not be reached for comment and the company gave only a short statement saying that indications from government agencies were negative and it elected to pull the application rather than proceed.
In the US, Sanofi's application to use Semuloparin to prevent venous thromboembolism (VTE) in cancer patients taking chemo was denied by the FDA who voted 14-1 against the application. Panel members commented that VTE events and deaths were no better than placebo.
No comments:
Post a Comment